PDS Biotechnology Corporation (NASDAQ:PDSB) saw a significant decline in short interest during the month of November. As of November 29th, there was short interest totalling 33,300 shares, a decline of 33.4% from the November 14th total of 50,000 shares. Based on an average trading volume of 90,800 shares, the days-to-cover ratio is currently 0.4 days. Approximately 1.2% of the company’s stock are sold short.
A number of brokerages recently issued reports on PDSB. Chardan Capital started coverage on shares of PDS Biotechnology in a research report on Wednesday, October 23rd. They set a “buy” rating and a $10.00 price objective for the company. HC Wainwright started coverage on shares of PDS Biotechnology in a research report on Tuesday, November 5th. They set a “buy” rating and a $7.00 price objective for the company.
Shares of PDS Biotechnology stock traded down $0.02 during trading on Thursday, reaching $2.72. The company’s stock had a trading volume of 11,317 shares, compared to its average volume of 73,424. The stock has a 50-day moving average price of $2.71. The company has a market capitalization of $16.64 million, a price-to-earnings ratio of -0.15 and a beta of 2.26. PDS Biotechnology has a fifty-two week low of $2.02 and a fifty-two week high of $11.80.
An institutional investor recently bought a new position in PDS Biotechnology stock. Amussen Hunsaker Associates LLC acquired a new position in PDS Biotechnology Corporation (NASDAQ:PDSB) during the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 14,641 shares of the company’s stock, valued at approximately $49,000. Amussen Hunsaker Associates LLC owned approximately 0.25% of PDS Biotechnology as of its most recent SEC filing. Hedge funds and other institutional investors own 8.83% of the company’s stock.
PDS Biotechnology Company Profile
PDS Biotechnology Corporation, a clinical stage immuno-oncology company, develops multifunctional immunotherapeutic products. The company develops products to treat early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers.
Featured Article: Liquidity
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.